SG2918

PreclinicalSmall molecule

HHangzhou Sumgen Biotech Co., Ltd.

SG2918 is one of 35 small molecule programs targeting Multiple Myeloma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Relapsed/refractory Multiple MyelomaRecruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Relapsed/refractory Multiple MyelomaPreclinical

Recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Nolvadex

AstraZeneca

Preclinical

1 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

Intron a

Systemic Therapy

1 10

Florbetaben

LLife Molecular Imaging GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Advanced Malignant Tumors

NCT06167486

Q4 2028

PreclinicalRecruiting

Relapsed/refractory Multiple Myeloma

NCT07454187

Clinical

Trials by Indication[1]

Advanced Malignant Tumors1 trial

SG2918 For Advanced Malignant Tumors

Active, not recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 1·NCT06167486·17 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 for Injection in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Preclinical·NCT07454187·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SG2918. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SG2918 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SG2918. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Sumgen Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHangzhou Sumgen Biotech Co., Ltd.

SG2918

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

Advanced Malignant Tumors1 trial

Relapsed/Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News